Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.CAMBREX CORPORATIONStatements of Profit and LossFor the Quarters Ended June 30, 2012 and 2011(in thousands, except per-share data)20122011% of% ofAmountSalesAmountSalesGross Sales
67,484Commissions, Allowances and Rebates781523Net Sales76,36166,961Other7721,421Net Revenues77,13368,382Cost of Goods Sold48,68863.1%49,32573.1%Gross Profit28,44536.9%19,05728.2%Operating ExpensesSelling, General and Administrative Expenses11,95915.5%9,19113.6%Research and Development Expenses2,5923.4%2,5723.8%Total Operating Expenses14,55118.9%11,76317.4%Operating Profit13,89418.0%7,29410.8%Other Expenses/(Income):Interest Expense, net678605Other Expenses/(Income), net16(282)Equity in Losses of Partially-Owned Affiliates383303Income Before Income Taxes12,81716.6%6,6689.9%Provision for Income Taxes2,8891,911Net Income
4,7577.0%Earnings per Share of Common Stock:Basic
|SOURCE Cambrex Corporation|
Copyright©2012 PR Newswire.
All rights reserved